Alteplase was not associated with a significant increase in mortality within 18 months ( 0.6 % [ 95 % confidence interval ( CI ) , -2.9 % to +4.2 ] P = 0.72 ] in all patients with complete vital status ( 99.9 % , 3034/3035 ) .